

May 2, 2018



## Trevena to Present at the Deutsche Bank 43rd Annual Healthcare Conference

CHESTERBROOK, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Deutsche Bank 43<sup>rd</sup> Annual Healthcare Conference on Tuesday, May 8<sup>th</sup>, 2018, at 3:30 p.m. EDT in Boston, MA.

To join a live audio webcast of the presentation, please visit the [Investor](#) section of the Company's website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

### About Trevena

Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.

### Contacts

Trevena, Inc.

#### Investors:

Jonathan Violin, Ph.D.  
Senior Vice President, Scientific Affairs & Investor Relations Officer  
610-354-8840 x231  
[jviolin@trevena.com](mailto:jviolin@trevena.com)

or

#### Media:

Public Relations  
[PR@trevena.com](mailto:PR@trevena.com)



Source: Trevena Inc.